1. Cell Cycle/DNA Damage
    Autophagy
    Antibody-drug Conjugate/ADC Related
  2. DNA Alkylator/Crosslinker
    Autophagy
    DNA/RNA Synthesis
    ADC Cytotoxin

Mitomycin C (Synonyms: Ametycine)

Cat. No.: HY-13316 Purity: 98.51%
Data Sheet SDS Handling Instructions

Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

For research use only. We do not sell to patients.
Mitomycin C Chemical Structure

Mitomycin C Chemical Structure

CAS No. : 50-07-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $58 In-stock
5 mg $53 In-stock
10 mg $70 In-stock
50 mg $220 In-stock
100 mg $300 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    Mitomycin C purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 30;7(1):4469.

    In order to normalize the potential effect of cell proliferation, Mitomycin C is added to the culture media to make the cells uniformly arrested. The results show that all migration cell indexes reduced after adding Mitomycin C than those observed without Mitomycin C. Knockdown of RAD51-AS1 still inhibits cell migration (A) and invasion of SKOV3, SKOV3.ip and HO8910 cells (B), while overexpression of RAD51-AS1 only increased cell invasion capacity of the OVCAR3 cells, not in the Hey cells (C).

    Mitomycin C purchased from MCE. Usage Cited in: Exp Cell Res. 2016 Feb 15;341(2):157-65.

    Curcumin inhibits the migration of BCPAP cells. Migration of cancer cells is assayed by wound-healing assay. Cells are cultured to nearly confluent cell monolayer and pretreated with Mitomycin C (10 μg/mL) for 2 h, followed by either DMSO or different dosages of curcumin for 6 h, before cells are wounded using yellow pipette tips. The cells are washed with PBS, and cultured for additional 24 h at 37 °C. (A) Photographs are taken after wound initially made and healing for 24 h. Data are represent
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

    IC50 & Target

    DNA synthesis[1]

    In Vitro

    The HCT116 (p53-/-) cells are minimally sensitive to either Mitomycin C or TRAIL alone. However, surprisingly, combination treatment with MMC and TRAIL decreases cell viability significantly. Although Mitomycin C and TRAIL alone are moderately effective, Mitomycin C substantially enhances the effect of TRAIL on suppression of the cell proliferation. Mitomycin C and TRAIL treatment alone induces 9.5% and 35.0% apoptosis, respectively. However, combination treatment with Mitomycin C and TRAIL enhances apoptosis to 66.6%[1]. Mitomycin C is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA cross-links as well as a variety of DNA monoadducts and is known to induce p53[2].

    In Vivo

    Mice bearing xenografted HCT116 (p53-/-) colon tumors and HT-29 colon tumors are treated with Mitomycin C (i.p., 1 mg/kg) and TRAIL (i.v., 100 μg) every other day. Animals are treated with 10 consecutive cycles of the combination therapy regimen. The combination therapy suppresses tumor growth significantly and does not impact the weight of the mice, indicating that the therapeutic combination of Mitomycin C and TRAIL is well-tolerated and has anti-tumor activity in vivo[1]. Intravesical Mitomycin C instillations has an effect on body weight that is not observed in normal, NaCl instilled or Epirubicin instilled rats. After 3 consecutive weekly instillations of 1 mg/mL Mitomycin C there is almost no weight gain, whereas rats in the other 3 groups has a statistically significant weight gain compared with MMC treated rats[3].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT02199327 Coordinación de Investigación en Salud, Mexico|Instituto Mexicano del Seguro Social|University of Guadalajara Conjunctival Intraepithelial Neoplasia|Corneal Intraepithelial Neoplasia May 2014 Phase 4
    NCT00966056 Karnataka Institute of Medical Sciences Nasal Synechiae|Adhesions of Nasal Cavity|Nasal Adhesions|Tissue Adhesions October 2007 Phase 2
    NCT00734994 Mark Dewhirst|Duke University Transitional Cell Carcinoma of Bladder|Superficial Bladder Cancer April 2008 Early Phase 1
    NCT01688024 Li, Zhiping, M.D.|Johns Hopkins University Primary Sclerosing Cholangitis September 2012 Phase 2
    NCT03073694 University of Kansas Medical Center Cancer, Appendiceal|ColoRectal Cancer Phase 2
    NCT01200992 Bioniche Life Sciences Inc. Bladder Neoplasm|Neoplasm Recurrence, Local|Transitional Cell, Carcinoma|Carcinoma in Situ|Mycobacterium November 2010 Phase 3
    NCT00551824 Federal University of São Paulo Esophageal Stricture|Caustic Esophageal Stricture|Peptic Esophageal Stricture|Post-Surgical Esophageal Stricture October 2007
    NCT00386399 Sidney Kimmel Comprehensive Cancer Center Pancreatic Cancer October 2006 Phase 2
    NCT01196455 Croatian Cooperative Group for Clinical Research in Oncology|Roche Pharma AG Breast Cancer|Metastasis March 2006 Phase 2
    NCT00564213 Instituto de Olhos de Goiania High Myopia March 2005 Phase 4
    NCT00626782 Wills Eye|Genentech, Inc.|Novartis Pharmaceuticals Glaucoma January 2008 Phase 2|Phase 3
    NCT00271011 University of Michigan Cancer Center Colorectal Cancer December 2005 Phase 2
    NCT01580410 Wake Forest University Health Sciences|National Cancer Institute (NCI) Carcinoma of the Appendix|Primary Peritoneal Cavity Cancer May 2009 Phase 2
    NCT00346489 Indiana University School of Medicine|Indiana University Glaucoma September 2004 Phase 4
    NCT01621217 Lund University Hospital|Merck Sharp & Dohme Corp. Locally Advanced Cancer in the Anal Region June 2012 Phase 1
    NCT02901236 Athens Vision Eye Institute Glaucoma January 2014 Phase 2|Phase 3
    NCT02316171 Viralytics Non-muscle Invasive Bladder Cancer December 2014 Phase 1
    NCT00974818 Memorial Sloan Kettering Cancer Center|New York Presbyterian Hospital|Weill Medical College of Cornell University Bladder Cancer September 2009 Phase 3
    NCT00192049 Eli Lilly and Company Superficial Bladder Cancer December 2003 Phase 2
    NCT00423293 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Anal Cancer December 2006 Phase 2
    NCT00999973 Shahid Beheshti University of Medical Sciences Myopia September 2009 Phase 1
    NCT03101501 Key-Whitman Eye Center Presbyopia February 14, 2017 Phase 4
    NCT00967291 IRCCS San Raffaele Pancreatic Cancer March 2006 Phase 2
    NCT02311101 The University of Texas Health Science Center at San Antonio Urinary Bladder Neoplasm March 2012 Phase 1
    NCT02948543 University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cancer Australia Bladder Cancer July 2013 Phase 3
    NCT02695771 Spectrum Health Hospitals Urinary Bladder Neoplasms April 2016 Phase 3
    NCT00294359 Australasian Gastro-Intestinal Trials Group Metastatic Colorectal Cancer June 2005 Phase 2|Phase 3
    NCT00289445 University Hospital Tuebingen Gastrointestinal Neoplasms|Neoplasm Metastasis September 1999 Phase 1|Phase 2
    NCT01648010 UroGen Pharma Ltd. Carcinoma of Urinary Bladder, Invasive November 2011
    NCT00918528 Hillel Yaffe Medical Center Urethral Stricture June 2009 Phase 1|Phase 2
    NCT00318643 Halozyme Therapeutics Bladder Cancer March 2006 Phase 1|Phase 2
    NCT01115517 The University of Texas Health Science Center, Houston|Hermann Eye Center Pterygium October 2010 Phase 2
    NCT00003710 The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific August 1998 Phase 1
    NCT02106572 Abnoba Gmbh Superficial Bladder Cancer February 2015 Phase 3
    NCT01167725 Walter Reed Army Medical Center|National Cancer Institute (NCI) Colorectal Cancer August 2010 Phase 3
    NCT00265863 Masonic Cancer Center, University of Minnesota Metastatic Cancer August 2004 Phase 2
    NCT00201747 Ohio State University Comprehensive Cancer Center|Pharmacia and Upjohn Esophageal Cancer|Esophagus Cancer|Cancer of Stomach|Stomach Cancer September 2001 Phase 2
    NCT00599950 Asociación para Evitar la Ceguera en México Refractive Disorders January 2007 Phase 4
    NCT01808495 Far Eastern Memorial Hospital Function of Mitomycin C in Cornea August 2012
    NCT00003003 Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) Leukemia September 1996 Phase 1
    NCT00949182 Rutgers, The State University of New Jersey Liver Cancer July 2009 Phase 2
    NCT00597181 Indiana University|Optonol Glaucoma November 2007 Phase 4
    NCT02560220 Heidelberg University|Grant: German government (EXIST Forschungstransfer, TolerogenixX, 03EFB BW56)|WiSP GmbH Kidney Failure, Chronic August 2015 Phase 1
    NCT00068744 European Organisation for Research and Treatment of Cancer - EORTC Anal Cancer July 2003 Phase 2|Phase 3
    NCT01094964 Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI) Bladder Cancer October 2009 Phase 3
    NCT02641132 Meir Medical Center Pterygium September 2015 Phase 4
    NCT01263834 Prince of Songkla University Glaucoma December 2010 Phase 2|Phase 3
    NCT00306852 University of Miami|Pfizer|Abbott Medical Optics Glaucoma October 1999
    NCT00854256 University of Cologne|iScience Interventional Corporation Glaucoma April 2009
    NCT00003018 Southwest Oncology Group|National Cancer Institute (NCI) Pancreatic Cancer September 1997 Phase 2
    NCT00002507 Yale University Carcinoma of Unknown Primary|Head and Neck Cancer November 1992 Phase 3
    NCT00042887 European Organisation for Research and Treatment of Cancer - EORTC Bladder Cancer May 2002 Phase 3
    NCT02092298 M.D. Anderson Cancer Center Gastrointestinal Cancer May 2014 Phase 2
    NCT00666237 University of Miami|Abbott Medical Optics|Research to Prevent Blindness|National Eye Institute (NEI) Glaucoma April 2008
    NCT00003596 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Southwest Oncology Group|North Central Cancer Treatment Group Anal Cancer October 1998 Phase 3
    NCT02070120 Institute of Cancer Research, United Kingdom|National Institute for Health Research, United Kingdom Bladder Cancer October 2014 Phase 2
    NCT00893490 Shahid Beheshti University of Medical Sciences Refractory Glaucoma Phase 1
    NCT00023842 European Organisation for Research and Treatment of Cancer - EORTC Bladder Cancer June 2001 Phase 2
    NCT00002993 Gynecologic Oncology Group|National Cancer Institute (NCI) Sarcoma August 1997 Phase 2
    NCT01011010 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Liver Cancer July 2009 Phase 1
    NCT00006112 Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) Carcinoma of the Appendix|Colorectal Cancer|Primary Peritoneal Cavity Cancer January 1996 Phase 2
    NCT02287389 Tang-Du Hospital|Changhai Hospital|The First Affiliated Hospital of Guangzhou Medical University|Xinqiao Hospital of Chongqing|China Meitan General Hospital|Micro-Tech (Nanjing) Co., Ltd. Obstructive Airway Disease December 2014
    NCT03126877 Whitten Laser Eye Presbyopia April 10, 2017 Phase 4
    NCT02710734 Fox Chase Cancer Center Urothelial Carcinoma of the Bladder February 2016 Phase 2
    NCT00981656 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Bladder Cancer November 2009 Phase 2
    NCT00024349 University Hospital Birmingham|National Cancer Institute (NCI) Bladder Cancer June 2001 Phase 3
    NCT00128037 Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan Pulmonary Neoplasm May 1999 Phase 2
    NCT02369939 University of Erlangen-Nürnberg Medical School Anal Carcinoma December 2014 Phase 3
    NCT00004887 The Christie NHS Foundation Trust|National Cancer Institute (NCI) Lung Cancer January 1999 Phase 3
    NCT00201396 National Health Research Institutes, Taiwan|National Taiwan University Hospital|Tri-Service General Hospital|Chang Gung Memorial Hospital|China Medical University Hospital|Chung Shan Medical University|Changhua Christian Hospital|Chi Mei Medical Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.|Taipei Veterans General Hospital, Taiwan Nasopharyngeal Carcinoma August 2003 Phase 3
    NCT00004209 Cancer Research UK|National Cancer Institute (NCI) Lung Cancer May 1998 Phase 3
    NCT00002490 Medical Research Council|National Cancer Institute (NCI) Bladder Cancer September 1991 Phase 3
    NCT01042041 Abramson Cancer Center of the University of Pennsylvania Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer September 2009 Phase 1
    NCT00005944 UNICANCER|National Cancer Institute (NCI) Colorectal Cancer|Metastatic Cancer|Primary Peritoneal Cavity Cancer November 1999 Phase 2
    NCT02724540 Abramson Cancer Center of the University of Pennsylvania Adults With Unresectable Liver-dominant Neuroendocrine Tumor Metastases That Are Are Symptomatic, Progressive, or Involve 25% of the Liver Volume March 2016 Phase 3
    NCT00025090 University College London (UCL) Cancer Institute|National Cancer Institute (NCI) Anal Cancer March 2001 Phase 3
    NCT03092518 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Gastric Adenocarcinoma|Esophagogastric Junction June 5, 2017 Phase 2
    NCT00005825 Raghu Nandan, M.D., Inc|National Cancer Institute (NCI) Lung Cancer September 1998 Phase 2
    NCT00030459 British Thoracic Society|Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma November 2000 Phase 2
    NCT00005870 Astex Pharmaceuticals|National Cancer Institute (NCI) Pancreatic Cancer March 1999 Phase 3
    NCT00033644 Gynecologic Oncology Group|National Cancer Institute (NCI) Sarcoma March 2002 Phase 2
    NCT01327521 Albert Koong|Accuray Incorporated|Stanford University Carcinoma, Hepatocellular February 2011 Phase 3
    NCT00075699 Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma September 2003 Phase 3
    NCT00652860 Mayo Clinic|National Cancer Institute (NCI) Metastatic Cancer|Sarcoma August 2001 Phase 2
    NCT00003240 National Cancer Institute (NCI) Lung Cancer October 1995 Phase 3
    NCT00023868 American College of Radiology Imaging Network|National Cancer Institute (NCI) Colorectal Cancer|Metastatic Cancer November 2001 Phase 3
    NCT00003159 Medical Research Council|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) Lung Cancer August 1997 Phase 3
    NCT00024271 Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) Malignant Mesothelioma May 2001 Phase 2
    NCT00003209 European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council Cervical Cancer December 1997 Phase 3
    NCT00276744 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Pancreatic Cancer October 2005 Phase 2
    NCT00003893 University Hospital Birmingham|National Cancer Institute (NCI) Breast Cancer July 1998 Phase 3
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 2.9911 mL 14.9553 mL 29.9106 mL
    5 mM 0.5982 mL 2.9911 mL 5.9821 mL
    10 mM 0.2991 mL 1.4955 mL 2.9911 mL
    Cell Assay
    [1]

    Mitomycin C is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1].

    Colon adenocarcinoma HCT116 and HT-29 human colon cancer cells are used. The CellTiter-Glo Luminescent Cell Viability Assay is used to measure cell viability, which use a unique, stable form of luciferase to measure ATP as an indicator of viable cells, and the luminescent signal produced is proportional to the number of viable cells present in culture. Cells are pretreated with Mitomycin C (5 μM) for 12 h or 24 h, and then exposed to different concentrations of TRAIL for 12 h. An equal volume (100 μL) of CellTiter-GloTM reagent is added and the solution is mixed gently for 2 min on an orbital shaker. Mixture is incubated at room temperature for 10 min to allow luminescent signal to stabilize, and then imaging is performed using the Xenogen IVIS system to quantify the cell viability[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1][3]

    Mitomycin C is prepared in saline (0.9% NaCl).

    Mice[1]
    Four- to 6-wk-old NCr nude mice are treated with Mitomycin C (1 mg/kg) by intraperitoneal injection for 24 h, followed by one intravenous dose of purified rhTRAIL (100 μg). As a negative control, a subset of the mice are injected (i.p. and i.v.) with saline (vehicle) at the same frequency of treatment. Animals are treated for 3 consecutive weeks. The tumor size is monitored every week using caliper measurements of the tumor volume.
    Rats[3]
    Young adult female Wistar rats at age 13 weeks with a median weight of 217 g (range 187 to 255) are randomized into 4 groups of 10 each, namely a normal group with no instillations, an NaCl 0.9% or placebo group that received instillations with the solvent of the chemotherapeutic agents, an Mitomycin C (1 mg/mL) group and an Epirubicin (1 mg/mL) group. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    334.33

    Formula

    C₁₅H₁₈N₄O₅

    CAS No.

    50-07-7

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: 30 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 98.51%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Mitomycin C
    Cat. No.:
    HY-13316
    Quantity: